Skip to content
DraconiticResearch
Search Sources API
197,768 studies31 sourcesUpdated 47 min ago
Peer-reviewedLicence not statedFuture Oncology

Efficacy of anlotinib plus immune checkpoint inhibitors in soft-tissue sarcoma: systematic review and meta-analysis

  • Ahmed Farid Gadelmawla1
  • Ahmed A. Abo Elnaga2
  • Abdullah Faisal Albukhari3
  • Raseel B. Almutairi4
  • Basmah Alamri5
  • Sami Mohammed Alhuways6
  • Fatemah Althaher7
  • Flwah Aloufi8
  • Abdullah Mohammed A. Alotaibi9
  • Abdullah Alali8
  • Ali Almatri10
  • Hamad Althawadi4
1 more authors
  • Abdullah Altamimi11
11 affiliations
  1. 1Faculty of Medicine, Menoufia University, Menoufia, Egypt
  2. 2Faculty of Medicine, Mansoura University, Mansoura, Egypt
  3. 3Faculty of Medicine, King Abdulaziz University, Rabigh, Saudi Arabia
  4. 4College of Medicine, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia
  5. 5College of Medicine, University of Jeddah, Jeddah, Saudi Arabia
  6. 6College of Medicine, Umm Al-Qura University, Makkah, Saudi Arabia
  7. 7Arabian Gulf University, Manama, Bahrain
  8. 8College of Medicine, Qassim University, Qassim, Saudi Arabia
  9. 9College of Medicine, Taif University, Taif, Saudi Arabia
  10. 10College of Medicine, King Saud University, Riyadh, Saudi Arabia
  11. 11Pediatric Emergency, King Fahad Medical City, Riyadh, Saudi Arabia
Read full textDOICite

Related

  1. Immune checkpoint inhibitors across neoadjuvant, perioperative, and adjuvant settings for resectable non-small-cell lung cancer: a systematic review and meta-analysis of randomized trials
    Jincan Dai, Mengni Liu, Hu Li +1
    Frontiers in pharmacologyPeer-reviewedCC BYFull textPharmacology & toxicologyEurope PMC
  2. Radiotherapy combined with anlotinib for recurrent high-grade soft tissue sarcoma of the scalp: a case report
    Bingxuan Li, Jinling Ren, Xiaoxia Song +1
    Frontiers in OncologyPeer-reviewedCC BY 4.0Full textOncologyCrossrefEurope PMCPMC
  3. Efficacy and Safety of Immune Checkpoint Inhibitors for Lung Cancer Complicated by Interstitial Pneumonia: The CS-Lung 003 Study, Branch Number 28.
    Kosuke Hamai, Nobuhiro Kanaji, Naoki Watanabe +12
    Thoracic cancerPeer-reviewedCC BYFull textOncologyEurope PMC
  4. Efficacy and Safety of Sequential Radiotherapy and Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma: A Single-Center PSM Retrospective Cohort Study.
    Huaxi Fan, Rong Yu, Guishu Wu +6
    Journal of hepatocellular carcinomaPeer-reviewedCC BY-NCFull textGeneral medicineEurope PMCPMC
  5. Efficacy and safety of immune checkpoint inhibitors combined with TKIs for recurrent or metastatic cervical cancer with PIK3CA mutation
    Lele Chang, Yaxin Kang, Mingxuan Zhu +3
    PLOS OnePeer-reviewedCC BY 4.0Full textOncologyPLOS

Cite

BibTeXRIS
BibTeX
@article{gadelmawla2026efficacy,
  title = {{Efficacy of anlotinib plus immune checkpoint inhibitors in soft-tissue sarcoma: systematic review and meta-analysis}},
  author = {Ahmed Farid Gadelmawla and Ahmed A. Abo Elnaga and Abdullah Faisal Albukhari and Raseel B. Almutairi and Basmah Alamri and Sami Mohammed Alhuways and Fatemah Althaher and Flwah Aloufi and Abdullah Mohammed A. Alotaibi and Abdullah Alali and Ali Almatri and Hamad Althawadi and Abdullah Altamimi},
  journal = {Future Oncology},
  year = {2026},
  month = sep,
  doi = {10.1080/14796694.2026.2730089},
  url = {https://doi.org/10.1080/14796694.2026.2730089},
}
RIS
TY  - JOUR
TI  - Efficacy of anlotinib plus immune checkpoint inhibitors in soft-tissue sarcoma: systematic review and meta-analysis
AU  - Ahmed Farid Gadelmawla
AU  - Ahmed A. Abo Elnaga
AU  - Abdullah Faisal Albukhari
AU  - Raseel B. Almutairi
AU  - Basmah Alamri
AU  - Sami Mohammed Alhuways
AU  - Fatemah Althaher
AU  - Flwah Aloufi
AU  - Abdullah Mohammed A. Alotaibi
AU  - Abdullah Alali
AU  - Ali Almatri
AU  - Hamad Althawadi
AU  - Abdullah Altamimi
PY  - 2026
DA  - 2026/09/19
JO  - Future Oncology
DO  - 10.1080/14796694.2026.2730089
UR  - https://doi.org/10.1080/14796694.2026.2730089
SN  - 1479-6694
SN  - 1744-8301
ER  -